New hope for Hard-to-Treat endometrial cancer: pfizer launches phase 3 trial
NCT ID NCT07578649
First seen May 16, 2026 · Last updated Jun 20, 2026 · Updated 10 times
Summary
This Phase 3 trial tests a new biologic drug (PF-08634404) plus chemotherapy against the approved drug Keytruda plus chemotherapy in 600 women with advanced or recurrent pMMR endometrial cancer. The goal is to see if the new combination helps patients live longer without their cancer worsening. Participants will be randomly assigned to one of two groups and receive treatment for up to two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nebraska Medicine - Bellevue Medical Center
Bellevue, Nebraska, 68123, United States
-
Nebraska Medicine - Cancer Center at Village Pointe Health Care
Omaha, Nebraska, 68118, United States
-
Nebraska Medicine - Nebraska Medical Center
Omaha, Nebraska, 68105, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-08634404 (a biologic drug) plus chemotherapy
What this could lead to
If it works, this could offer a new treatment option for people with advanced or recurrent pMMR endometrial cancer, potentially improving how long they live without the cancer growing.
What could go wrong
This is an early-stage Phase 3 trial that hasn't started recruiting yet. The new drug may not be more effective than the existing treatment (Keytruda), and side effects from combining it with chemotherapy are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.